Imatinib Mesylate Tablet | Study Design

Imatinib Mesylate Tablets- FDA & EMA – BE Study Design

Regulatory Body FDA/EMA
Study Drug Information Test Product Reference Product
Strength Imatinib 400 mg FDA: Gleevec 400 mg
EMA: Gilvec 400 mg film-coated tabelts
Formulation Tablets tablets
Manufacturer Any Sponsor Novartis
Route Oral Oral
Therapeutic Indication Therapeutic Class: Oncology
Therapeutic Indication: used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases)


Interested in the Full Study Design? Click below to download.

Schedule a Discovery Call

 Learn how BioPharma Services can be your trusted clinical trial partner.

You can unsubscribe at any time. For more details, please read our Privacy Policy.